Monday, November 14, 2022 11:49:58 AM
PDSB Update:
PDSB the price per share is $7.27
+$1.67 (29.82%)
Volume
11,876,752
---------------------------------------------
I got in at 6.93, after alerting here.
------------------------------------------------
https://stockcharts.com/h-sc/ui?s=PDSB
------------------------------------------------------
BRIEF-Pds Biotech Announces 100% Clinical Response In Cervical Cancer Patients In Mid-stage Study
By Reuters — 7:51 AM ET 11/14/22
Nov 14 (Reuters) - Pds Biotechnology Corp (PDSB.NaE):
* PDS BIOTECH ANNOUNCES 100% CLINICAL RESPONSE IN CERVICAL CANCER PATIENTS IN PRELIMINARY DATA FROM IMMUNOCERV PHASE 2 CLINICAL TRIAL
* 89% (8/9) HAD NO EVIDENCE OF DISEASE (COMPLETE RESPONSE) ON DAY 170.
\---------------------------------------
PDS Biotechnology Q3 EPS $(0.26) Beats $(0.28) Estimate. Cash Balance Of Approximately $71.6M
By Benzinga — 7:32 AM ET 11/14/22
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 8.33 percent decrease over losses of $(0.24) per share from the same period last year.
PDSB the price per share is $7.27
+$1.67 (29.82%)
Volume
11,876,752
---------------------------------------------
I got in at 6.93, after alerting here.
------------------------------------------------
https://stockcharts.com/h-sc/ui?s=PDSB
------------------------------------------------------
BRIEF-Pds Biotech Announces 100% Clinical Response In Cervical Cancer Patients In Mid-stage Study
By Reuters — 7:51 AM ET 11/14/22
Nov 14 (Reuters) - Pds Biotechnology Corp (PDSB.NaE):
* PDS BIOTECH ANNOUNCES 100% CLINICAL RESPONSE IN CERVICAL CANCER PATIENTS IN PRELIMINARY DATA FROM IMMUNOCERV PHASE 2 CLINICAL TRIAL
* 89% (8/9) HAD NO EVIDENCE OF DISEASE (COMPLETE RESPONSE) ON DAY 170.
\---------------------------------------
PDS Biotechnology Q3 EPS $(0.26) Beats $(0.28) Estimate. Cash Balance Of Approximately $71.6M
By Benzinga — 7:32 AM ET 11/14/22
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 8.33 percent decrease over losses of $(0.24) per share from the same period last year.
Recent PDSB News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:07:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:05:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 04:26:02 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/29/2026 04:15:10 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/28/2026 08:30:50 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 04/27/2026 03:51:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 12:55:12 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:39:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:05:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:47:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 05:01:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:05:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 01:35:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 01:50:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2026 01:50:53 PM
- Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 • PR Newswire (Canada) • 01/12/2026 03:35:00 PM
- Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 • PR Newswire (US) • 01/12/2026 03:35:00 PM
